# A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

> **NCT06147570** · PHASE2 · RECRUITING · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 62 (estimated)

## Conditions studied

- Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** HS-10365 capsules

## Key facts

- **NCT ID:** NCT06147570
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-25
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2023-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06147570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06147570, "A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06147570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*